Navigation Links
Despite Earlier Doubts, Feinstein Study Shows Fetal Transplants May Benefit Parkinson's Patients Over Age 60
Date:12/31/2009

Fetal transplant surgery for Parkinson’s disease went on experimentally for more than a decade before it was put to the ultimate test in a double-blind, randomized study.

Manhasset, NY (Vocus) December 31, 2009 -- Fetal transplant surgery for Parkinson’s disease went on experimentally for more than a decade before it was put to the ultimate test in a double-blind, randomized study. It turned out that only patients under 60-years-old showed any benefit, but some also developed uncontrolled jerking movements that washed away hope for the technique. The findings were the death knell for the promising procedure.

But scientists involved with brain imaging studies of the fetal transplant recipients did not put away their study tools. In fact, they kept bringing the Parkinson’s patients back into the laboratory to take snapshots of their brains over time. And what they have now found, and reported in the latest issue of The Journal of Nuclear Medicine (JNM), is that people over age 60 began to show improvements more than a year after fetal dopamine cells were infused into the brain region damaged by Parkinson’s.

“This was totally surprising,” said David Eidelberg, MD, director of the Center for Neurosciences at The Feinstein Institute for Medical Research in Manhasset, NY. “The use of fetal transplantation for Parkinson’s encountered a good deal of skepticism after five patients in the study (all under age 60) developed dyskinesias.”

Dr. Eidelberg said that the Parkinson’s community basically forgot about the research and turned their attention to other promising techniques.

There were 33 patients, 13 of whom were over age 60 when the cells were infused into their brains. It was a double-blinded study so that 19 patients received the fetal cells and 14 others had a sham surgery and were offered the fetal cell transplant a year later. But by that time, the word had come out about the devastating side effect (the dyskinesias) and some older people opted out of the second surgery.

The Feinstein researchers have now looked at the brains of the transplanted patients two years and four years after the initial infusion of fetal cells. And they learned a few things: Beyond the first five people who developed dyskinesia, none of the other 15 younger people in the study showed signs of the troubling side effect. In about 25 percent of the cases, clinical improvement was noted and the transplanted cells were still working to make the dopamine up to four years later.

They also discovered that the older people gradually got better after the first year and that their improvements continued over the long term. “The older the brain, the harder it is to integrate the graft,” said Dr. Eidelberg. “But the PET scans told us that the graft was viable. And it took awhile before the cells worked to improve symptoms.”

The Feinstein group has identified two different brain networks hard hit in the disease. One is obvious: the motor regions that, when damaged, lead to tremors, rigidity and difficulty initiating movement. The other piece relates to cognition and mood, and there are discrete brain regions that worsen over time. In this study, researchers found that people did better overall on motor functions if they entered the study with their putamen intact – putamen is an area of the brain that governs cognition and mood. Dopamine is the key brain chemical in both these networks and it is critical for motor planning. When dementia sets in, people may have improvements in the motor network, but it isn’t observable because their cognitive network is abnormal and their ability to make plans to move is impaired.

The good news, said Dr. Eidelberg, is that the grafts stayed where they were and delivered dopamine to the tissue. The finding is critical as the field moves to transplant other types of cells, including embryonic stem cells or their ultimate product.

Much of the work for this study was conducted by Feinstein scientist Yilong Ma, MD, in collaboration with Dr. Eidelberg. The fetal cell transplant study was conducted by Paul Greene, MD, and Stanley Fahn, MD, Department of Neurology, Columbia College of Physicians and Surgeons, New York, New York and Robert Breeze, MD, Department of Neurosurgery, University of Colorado School of Medicine, Denver, Colorado; and Curt Freed, MD, Neuroscience Center and Division of Clinical Pharmacology and Toxicology, University of Colorado School of Medicine, Denver, Colorado.

About The Feinstein Institute for Medical Research
Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research (www.feinsteininstitute.org) is home to international scientific leaders in cancer, leukemia, lymphoma, Parkinson's disease, Alzheimer’s disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, inflammatory bowel disease, diabetes, human genetics, neuroimmunology, and medicinal chemistry. Feinstein researchers are developing new drugs and drug targets, and producing results where science meets the patient, annually enrolling some 10,000 subjects into clinical research programs.

Contact: Jamie Talan, science writer-in-residence,
516-562-1232 or email JTalan3k(at)aol(dot)com

# # #

Read the full story at http://www.prweb.com/releases/Fetal_Transplant_Surgery/Parkinsons_Disease/prweb3388034.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Coalition for Pulmonary Fibrosis Celebrates Successes Despite Year of Economic Downturn
2. Health Reform Bill Needs More Work Despite New Language on Abortion, Say Catholic Bishops
3. Despite Early Uptake, Seasonal Flu Vaccination Rates are Similar to Last Year
4. The Logo Loft Hires Laid-Off Sales Executive Increasing Sales for Company by 15% Despite the Recession
5. XOLAIR Safety Study Continues to 2012 Despite Increased Rate of Occurrence of Heart Problems, Onder Law Firm Offers Free XOLAIR Case Review
6. Apple Vending is a Strong Growth Segment Despite Tough Economic Times
7. Houston Plastic Surgeon Seeing Growth in Aesthetic Enhancement Procedures Despite Rough Economy
8. Major health care challenges persist for D.C. children despite high rates of health insurance coverage, RAND study finds
9. Gross Germ-Spreading Behaviors Remain the Norm, Despite Flu Season Concerns
10. National Autism Association Maintains Support of Travoltas Despite Whoopi Goldbergs Mistaken Comments on ABCs The View
11. Despite size, NFL players not more likely to develop heart disease, even after retirement
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Despite Earlier Doubts, Feinstein Study Shows Fetal Transplants May Benefit Parkinson's Patients Over Age 60
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook a hot ... suggests that Americans prefer their dogs straight off the grill. Of the 90 percent ... favorite way to cook a hot dog, far outpacing other cooking methods such as ...
(Date:5/26/2016)... ... , ... Connor Sports, through its Connor Cares initiative, will continue ... Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and ... forms and levels of the game, Connor Sports has committed to a significantly increased ...
(Date:5/26/2016)... ... ... MadgeTech will be showcasing its line of data logging products , ... MadgeTech headquarters. With products sold in more than 100 countries around the world, MadgeTech ... , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data loggers around ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the ... Insurance is sharing tips to make sure your family and vehicle are ready ... Safety Council, there may be 439 deaths and an additional 50,500 serious injuries from ...
(Date:5/26/2016)... Rafael, CA (PRWEB) , ... May 26, 2016 ... ... will be offering campers a multitude of activities from daily practices, arts & ... self-confidence. , Camp Directors Amber East-D’Anna and Christy Evans have combined backgrounds in ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... May 25, 2016 MedDay, a biotechnology ... that an oral presentation entitled "High doses of biotin in ... will be given by Professor Ayman Tourbah , Principal ... of the European Academy of Neurology (EAN) in ... disorders 3" will take place on Sunday, 29 May 2016 ...
(Date:5/24/2016)... 24, 2016   ... primären Endpunkte und demonstriert Ebenbürtigkeit bei ... ‚ausgezeichneter plus guter , ...      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) ... positive Daten von der MORA-Studie der Phase III ...
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
Breaking Medicine Technology: